Stock Recommendations and Results

AlphaProfit puts stocks under the microscope to provide you reliable winning stock recommendations. The stock recommendations supplement AlphaProfit’s ETF and mutual fund recommendations providing you multiple ways to make money.

Leaving nothing to chance, AlphaProfit evaluates stocks on both fundamental and technical factors … fundamentals to make sure that companies are worthy of committing your precious dollars from quality, valuation, and growth perspectives, and technicals to provide you laser-cut buy and sell price points.

Additionally, each recommended stock has a unique catalyst that speeds the time you need to realize your profit and at the same time … reduces your risk.

The result … you go from winner to winner rapidly growing your money.

The performance reported here are based on EXACT buy and sell price points AlphaProfit provides with each stock recommendation making results easily verifiable. The reported returns assume reinvestment of dividends; they do not account for brokerage commission expenses.

Performance of Filled Recommendations

December 31, 2008 to December 31, 2018

Win Rate: 86%

Avg. Return: 12.0%

Avg. Holding Period: 2 months

Implied Annualized Return: 84%


 I do not know of any other service that makes stock investing so easy and is always on target. I have made quite a bundle with the precise buy and sell price points your stock recommendations include. 

William C., Chapel Hill, NC


Examples of Stock Recommendations and Results

CVS Health (CVS)

What AlphaProfit Said

Buy Below: $68.75    Sell Above: $77.50

CVS Health expects regulators to approve its $69 billion purchase of Aetna before year-end, making CVS one of the most vertically integrated healthcare companies. CVS has announced the merged entity’s management and set up an integration team after shareholders approved the deal. Ahead of the merger, CVS by itself is executing well. It beat analysts’ first-quarter EPS estimate by 5% and raised its 2018 EPS forecast range to imply 18% growth at the mid-point. Yielding 3.0%, CVS shares interest value investors. They trade at 9.6X-2018 EPS forecast, well-below their historical multiple. (Next earnings: August 8)

What Subscribers Got

18% Profit

  • Bought at $66.35 on Jun. 12, 2018
  • Sold at $77.50 on Sep. 10, 2018
  • Holding period of 3 months


Petrobras (PBR)

What AlphaProfit Said

Buy Below: $10.45    Sell Above: $12.60

Petrobras shares lost 30% of their value in the latter part of May after Brazil’s government-controlled refined product prices were impacted by a trucker’s strike. The oil & gas company’s second-quarter results mitigate concerns and show continued progress in reducing debt. Petrobras’ free cash flow more than doubled to BRL 11 billion from higher oil prices and asset sales. The company pared debt by $5 billion to about $73 billion. Appealing to risk-tolerant value investors, Petrobras ADS trade at parity to book value and at 6.4X-forward EPS versus prospects for 48% improvement in EPS over the next 12 months. (Next earnings: November 5)

What Subscribers Got

22% Profit

  • Bought at $10.45 on Aug. 20, 2018
  • Sold at $12.80 on Oct. 2, 2018
  • Holding period of 6 weeks


SkyWest (SKYW)

What AlphaProfit Said

Buy Below: $48.80    Sell Above: $54.30

Shares of regional airline SkyWest are down 23% from their August close. Operational changes at SkyWest should help buck the negatives impacting other carriers. SkyWest is improving operating margin by replacing its turboprop fleet with larger E175 aircraft. Its troubled subsidiary ExpressJet should finally turn profitable in 2019. Demand for SkyWest’s regional network should benefit as major airlines grow capacity. Investors seeking growth-at-a-reasonable-price should find SkyWest shares appealing. They trade at 9.6X-forward EPS versus prospects for 21% EPS growth in the next 12 months. (Next earnings: October 30)

What Subscribers Got

18% Profit

  • Bought at $48.80 on Oct. 24, 2018
  • Sold at $57.74 on Oct. 31, 2018
  • Holding period of 7 days